ABSTRACT Objective: To explore characteristics of influence of aminophenol oxycodone on liver function, and to provide evidence for improving drug safety. Methods:A total of 1 435 inpatients using aminophenol oxycodone tablets from August 2017 to July 2018 in our hospital were transferred. Then, patients' basic data, medication status and liver function indicators were statistically analyzed. Results:The incidence of liver damage caused by aminophenol oxycodone in 1 435 patients was only 1.39%. Among them, 30 to 39 years old and 60 to 69 years old patients were more. In 20 patients with liver injury, the incidence of liver injury in headache patients was the highest (10.00%) in different types of pain. The incidence of liver injury in patient treated by aminophenol oxycodone in 660 mg, qd was the highest in different administration dosages. 9 patients with liver damage occurred within 1 to 3 days of treatment. Before withdrawal, the levels of ALT, AST and AST/ALT in patients with liver damage were significantly higher than those before treatment, and the difference was statistically significant (P<0.05). However, there was no significant change in TBil, DBil and IBil, and the difference was not statistically significant (P>0.05). After one week of withdrawal and symptomatic treatment, the serum aminotransferase level of the patient returned to normal, and there was no significant difference compared with before treatment (P>0.05). Conclusion:Liver damage caused by aminophenol oxycodone is a drug induced liver injury of the type of hepatocyte injury. The symptoms are mild and reversible, but should still cause clinical attention. |